BDMD

Baird Medical Investment Holdings Ltd Ordinary Share
BDMD
Market cap $107M

3.02 USD

-0.04

1.31%

At close Oct 18, 4:00 PM EDT

1 day

-1.31%

5 days

-12.46%

1 month

-39.60%

3 months

-39.60%

6 months

-39.60%

Year to date

-39.60%

1 year

-39.60%

5 years

-39.60%

About: Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.

–

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BDMD.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about BDMD published over the past 30 days

Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting

NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices in China, which recently expanded into the U.S. market following its U.S. FDA 510(k) clearances, today announced its participation in the upcoming American Thyroid Association (ATA) Annual Meeting.

Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting

Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024

Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China , Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced its preliminary financial results for the six months ended June 30, 2024 (the "First Half of 2024").

Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C. , Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd.

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference

GUANGZHOU, China , Oct. 8, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced that the Company will participate in the following investor conference.

Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference

See News Rankings

Charts implemented using Lightweight Charts™